Document

Systematic Reviewer (Researcher) – FSRH Clinical Effectiveness Unit- Job Description

Clinical Director – FSRH Clinical Effectiveness Unit - Job Description

Examiners Conference 2023 - Certificate of Attendance

15th September 2023

Here is the full-day agenda for the Examiners Conference 2023, taking place at RCOG Friday 15 September.

A study published today in the Lancet reports that a combination of levonorgestrel 1.5mg with piroxicam is more effective for emergency contraception than levonorgestrel 1.5mg alone.

This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any healthcare professional or health service providing contraceptive care in the UK. In this version of the POP Guideline, the supporting evidence for the recommendations has been removed from the main text and located in an appendix for ease of reading. This document is available to FSRH members and candidates only. 

The guideline provides evidence-based recommendations and good practice points to enable clinicians to support individuals to make informed decisions about choosing and using IUC. It includes information on assessing suitability of IUC use for contraception, the risks and benefits of IUC and guidance for IUC procedures, complications and follow-up. Published March 2023.

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023)

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

FSRH CEU Statement: Response to Study: Intrauterine Contraception Use and Cervical Cancer Risk (January 2018)

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

The digital version can be accessed from the BMJ SRH website: FSRH Guideline (March 2023) Intrauterine contraception BMJ Sexual & Reproductive Health 2023;49:1-142. 

This document updates previous Faculty of Sexual & Reproductive Healthcare (FSRH) guidance and aims to summarise the available evidence on emergency contraception (EC). The guidance is intended for use by health professionals providing EC. 

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement Response to Edelman 2022 (August 2022)

FSRH CEU Statement: Response to Endler 2022 (July 2022)

FSRH CEU Statement: Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study (August 2018)

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids (February 2018)

FSRH CEU Statement: Response to Recent Publication Regarding Banh, et al - November 2020

FSRH CEU Statement: Response to Recent Publication Turok et al. (2021) - February 2021

This update of the 2010 Contraception for Women Aged Over 40 Years guideline has been developed by the FSRH and brings together evidence and expert opinion on contraception for women aged over 40 years. The guideline was developed with a team of experts in the relevant fields and has been extensively peer reviewed in accordance with methodology used for developing FSRH Clinical Guidelines. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings. 

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on progestogen-only contraceptive pills. Please refer to the full 2022 FSRH Progestogen-only Pills Clinical Guideline for further information and supporting evidence for this advice. This document is written for FSRH members and requires you to log in to access it.